Dr. Daniel Drucker, an endocrinologist and a clinician-scientist at the University of Toronto and the Lunenfeld-Tanenbaum ...

Eli Lilly is suing two pharmacies for compounding Zepbound and Mounjaro, claiming the companies are skirting the Food and Drug Administration's ban on the practice and luring people away from ...

Tirzepatide is the ingredient behind Lilly's major obesity and diabetes franchise Zepbound and Mounjaro and works as a long-acting GIP (glucose-dependent insulinotropic polypeptide) receptor and ...

Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, developed by Eli Lilly and Company, targets both GIP and GLP-1 receptors ...

The robust pipeline is a result of Lilly's strong commitment to research. We believe cardiometabolic drugs Mounjaro, Zepbound, and Jardiance as well as immunology drug Taltz, cancer drug Verzenio ...

Since 2023, Lilly has taken action against dozens of pharmacies, weight-loss centers and health spas over the drugs Mounjaro and Zepbound accounted for more than one-third of Lilly’s record $45 ...